Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 253

1.

Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms.

Daly AK.

Arch Toxicol. 2013 Mar;87(3):407-20. doi: 10.1007/s00204-013-1013-9. Epub 2013 Feb 2. Review.

PMID:
23376975
2.

Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon.

Beinema M, Brouwers JR, Schalekamp T, Wilffert B.

Thromb Haemost. 2008 Dec;100(6):1052-7. Review.

PMID:
19132230
3.

Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population.

Rusdiana T, Araki T, Nakamura T, Subarnas A, Yamamoto K.

Eur J Clin Pharmacol. 2013 Mar;69(3):395-405. doi: 10.1007/s00228-012-1356-9. Epub 2012 Aug 2.

PMID:
22855348
4.

A new algorithm to predict warfarin dose from polymorphisms of CYP4F2 , CYP2C9 and VKORC1 and clinical variables: derivation in Han Chinese patients with non valvular atrial fibrillation.

Wei M, Ye F, Xie D, Zhu Y, Zhu J, Tao Y, Yu F.

Thromb Haemost. 2012 Jun;107(6):1083-91. doi: 10.1160/TH11-12-0848. Epub 2012 Apr 26.

PMID:
22534826
5.

Pharmacogenetics of oral anticoagulants: a basis for dose individualization.

Stehle S, Kirchheiner J, Lazar A, Fuhr U.

Clin Pharmacokinet. 2008;47(9):565-94. Review.

PMID:
18698879
6.

Creating a genotype-based dosing algorithm for acenocoumarol steady dose.

Cerezo-Manchado JJ, Rosafalco M, Antón AI, Pérez-Andreu V, Garcia-Barberá N, Martinez AB, Corral J, Vicente V, González-Conejero R, Roldán V.

Thromb Haemost. 2013 Jan;109(1):146-53. doi: 10.1160/TH12-08-0631. Epub 2012 Nov 29.

PMID:
23196355
7.

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population.

Ozer N, Cam N, Tangurek B, Ozer S, Uyarel H, Oz D, Guney MR, Ciloglu F.

Heart Vessels. 2010 Mar;25(2):155-62. doi: 10.1007/s00380-009-1177-7. Epub 2010 Mar 26.

PMID:
20339978
8.

Genetic determinants of acenocoumarol and warfarin maintenance dose requirements in Slavic population: a potential role of CYP4F2 and GGCX polymorphisms.

Wypasek E, Branicka A, Awsiuk M, Sadowski J, Undas A.

Thromb Res. 2014 Sep;134(3):604-9. doi: 10.1016/j.thromres.2014.06.022. Epub 2014 Jul 7.

PMID:
25042728
9.

The VKORC1 and CYP2C9 genotypes are associated with over-anticoagulation during initiation of warfarin therapy in children.

Biss TT, Avery PJ, Williams MD, Brandão LR, Grainger JD, Kamali F.

J Thromb Haemost. 2013 Feb;11(2):373-5. doi: 10.1111/jth.12072. No abstract available.

10.

VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.

Shaw K, Amstutz U, Hildebrand C, Rassekh SR, Hosking M, Neville K, Leeder JS, Hayden MR, Ross CJ, Carleton BC.

Pediatr Blood Cancer. 2014 Jun;61(6):1055-62. doi: 10.1002/pbc.24932. Epub 2014 Jan 29.

PMID:
24474498
11.

Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups.

Scott SA, Khasawneh R, Peter I, Kornreich R, Desnick RJ.

Pharmacogenomics. 2010 Jun;11(6):781-91. doi: 10.2217/pgs.10.49.

12.

Warfarin dose prediction in children using pharmacometric bridging--comparison with published pharmacogenetic dosing algorithms.

Hamberg AK, Friberg LE, Hanséus K, Ekman-Joelsson BM, Sunnegårdh J, Jonzon A, Lundell B, Jonsson EN, Wadelius M.

Eur J Clin Pharmacol. 2013 Jun;69(6):1275-83. doi: 10.1007/s00228-012-1466-4. Epub 2013 Jan 11. Erratum in: Eur J Clin Pharmacol. 2013 Sep;69(9):1737.

13.

Influence of UDP-Glucuronosyltransferase Polymorphisms on Stable Warfarin Doses in Patients with Mechanical Cardiac Valves.

An SH, Chang BC, Lee KE, Gwak HS.

Cardiovasc Ther. 2015 Dec;33(6):324-8. doi: 10.1111/1755-5922.12147.

PMID:
26223945
14.

Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements.

Cadamuro J, Dieplinger B, Felder T, Kedenko I, Mueller T, Haltmayer M, Patsch W, Oberkofler H.

Eur J Clin Pharmacol. 2010 Mar;66(3):253-60. doi: 10.1007/s00228-009-0768-7. Epub 2009 Dec 18.

PMID:
20020283
15.

Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin.

Teh LK, Langmia IM, Fazleen Haslinda MH, Ngow HA, Roziah MJ, Harun R, Zakaria ZA, Salleh MZ.

J Clin Pharm Ther. 2012 Apr;37(2):232-6. doi: 10.1111/j.1365-2710.2011.01262.x. Epub 2011 Apr 20.

PMID:
21507031
16.

Influence of warfarin dose-associated genotypes on the risk of hemorrhagic complications in Chinese patients on warfarin.

Ma C, Zhang Y, Xu Q, Yang J, Zhang Y, Gao L, Xu B, Wang H, Li Y, Lu C, Yin T.

Int J Hematol. 2012 Dec;96(6):719-28. doi: 10.1007/s12185-012-1205-8. Epub 2012 Oct 27.

PMID:
23104259
17.

Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.

Carlquist JF, Horne BD, Muhlestein JB, Lappé DL, Whiting BM, Kolek MJ, Clarke JL, James BC, Anderson JL.

J Thromb Thrombolysis. 2006 Dec;22(3):191-7.

PMID:
17111199
18.

Validation of pharmacogenetic algorithms and warfarin dosing table in Egyptian patients.

Bazan NS, Sabry NA, Rizk A, Mokhtar S, Badary O.

Int J Clin Pharm. 2012 Dec;34(6):837-44. doi: 10.1007/s11096-012-9678-3. Epub 2012 Jul 27.

PMID:
22851439
19.

Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients.

Liang R, Li L, Li C, Gao Y, Liu W, Hu D, Sun Y.

J Thromb Thrombolysis. 2012 Jul;34(1):120-5. doi: 10.1007/s11239-012-0725-7.

PMID:
22528326
20.

Patients benefit from genetics-guided coumarin anticoagulant therapy.

Maitland-van der Zee AH, Daly AK, Kamali F, Manolopoulous VG, Verhoef TI, Wadelius M, de Boer A, Pirmohamed M; EU-PACT Study Group..

Clin Pharmacol Ther. 2014 Jul;96(1):15-7. doi: 10.1038/clpt.2014.44. Erratum in: Clin Pharmacol Ther. 2014 Sep;96(3):397. Manolopoulos, V G [corrected to Manolopoulous, V G].

PMID:
24942396

Supplemental Content

Support Center